the problem Obagi Condition and Enhance Generic Name: hydroquinone Dosage Form: cream Side Effects Dosage Professional Pregnancy Reviews More Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here. Obagi Condition & Enhance Clear (Hydroquinone USP, 4%) Skin Bleaching Cream Obagi Condition & Enhance Blender (Hydroquinone USP, 4%) Skin Bleaching Cream Rx Only FOR EXTERNAL USE ONLY Slideshow ADHD and Your Child: Signs and Treatment Options Obagi Condition and Enhance Description Hydroquinone is 1,4-benzenediol. Hydroquinone occurs as fine, white needles. The drug is freely soluble in water and in alcohol. Chemically, hydroquinone is designated as p-dihydroxybenzene; the empirical formula is C 6 H 6 O 2 ; molecular weight is 110.0. Obagi Condition & Enhance Blender contains Hydroquinone USP 40 mg/gm in a base of purified water, glycerin, cetyl alcohol, PPG-2 myristyl ether propionate, sodium lauryl sulfate, TEA-salicylate, lactic acid, phenyl trimethicone, tocopheryl acetate, sodium metabisulfite, ascorbic acid, methylparaben, saponins, disodium EDTA, BHT, and propylparaben. Obagi Condition & Enhance Clear contains Hydroquinone USP 40 mg/gm in a base of purified water, cetyl alcohol, glycerin, sodium lauryl sulfate, stearyl alcohol, tocopheryl acetate, ascorbic acid, sodium metabisulfite, lactic acid, saponins, disodium EDTA, methylparaben, BHT, propylparaben, and butylparaben. Obagi Condition and Enhance - Clinical Pharmacology Topical application of hydroquinone produces a reversible depigmentation of the skin by inhibition of the enzymatic oxidation of tyrosine to 3, 4-dihydroxyphenylalanine (dopa) and suppression of other melanocyte metabolic processes. Exposure to sunlight or ultraviolet light will cause repigmentation of the bleached areas, which may be prevented by the use of sunblocking agents or sunscreen agents contained in Obagi Condition & Enhance. Indications and Usage for Obagi Condition and Enhance The gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation. Contraindications Prior history of sensitivity or allergic reaction to this product or any of its ingredients. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established. Warnings Caution Hydroquinone is a skin bleaching agent which may produce unwanted cosmetic effects if not used as directed. The physician should be familiar with the contents of this insert before prescribing or dispensing this medication. Test for skin sensitivity before using by applying a small amount to an unbroken patch of skin and check in 24 hours. Minor redness is not a contraindication, but where there is itching or vesicle formation or excessive inflammatory response, further treatment is not advised. Close patient supervision is recommended. Avoid contact with eyes. In case of accidental contact, patient should rinse eyes thoroughly with water and contact physician. A bitter taste and anesthetic effect may occur if applied to lips. Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity. Warning Contains sodium metabisulfite, a sulfite that may cause serious allergic type reactions (e.g., hives, itching, wheezing, anaphylaxis, severe asthma attacks) in certain susceptible persons. Precautions (SEE WARNINGS ) General Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation which does not preclude treatment. Pregnancy Category C Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity. It is not known to what degree, if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used on pregnant women only when clearly indicated. Nursing mothers It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother. Pediatric usage Safety and effectiveness in children below the age of 12 years have not been established. Adverse Reactions No systemic adverse reactions have been reported. Occasional hypersensitivity (localized contact dermatitis) may occur, in which case the medication should be discontinued and the physician notified immediately. Obagi Condition and Enhance Dosage and Administration A thin application should be applied to the affected area twice daily or as directed by a physician. If no improvement is seen after three (3) months of treatment, use of this product should be discontinued. Sun exposure should be limited by using a sunscreen agent, a sun blocking agent, or protective clothing to cover bleached skin when using and after using this product in order to prevent repigmentation. How is Obagi Condition and Enhance Supplied Obagi Condition and Enhance Blender is available as follows: 2 oz. (57 gm) bottle NDC 62032-115-36 1 oz. (28.5 gm) bottle NDC 62032-115-10 Obagi Condition and Enhance Clear is available as follows: 2 oz. (57 gm) bottle NDC 62032-117-36 Store at 25 C (77 F); excursion permitted to 15 C-30 C (59 F-86 F). OBAGI MEDICAL OMP, Inc. Long Beach, CA 90802 USA 1-800-636-7546 80707910U Rev. 6/07 PRINCIPAL DISPLAY PANEL - 57 g Bottle Label OBAGI MEDICAL CONDITION & ENHANCE NDC 62032-117-36 AM PM 3 clear Skin Bleaching & Corrector Cream Hydroquinone USP, 4% Rx Only NET WT. 2 OZ. (57 g) PRINCIPAL DISPLAY PANEL - 57 g Bottle Label OBAGI MEDICAL CONDITION & ENHANCE NDC 62032-115-36 PM 5 blender Skin Lightener & Blending Cream Hydroquinone USP, 4% Rx Only NET WT. 2 OZ. (57 g) CONDITION AND ENHANCE CLEAR SKIN BLEACHING AND CORRECTOR hydroquinone cream Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:62032-117 Route of Administration TOPICAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength HYDROQUINONE (HYDROQUINONE) HYDROQUINONE 40 mg in 1 g Inactive Ingredients Ingredient Name Strength EDETATE DISODIUM BUTYLPARABEN STEARYL ALCOHOL SODIUM LAURYL SULFATE CETYL ALCOHOL GLYCERIN LACTIC ACID ALPHA-TOCOPHEROL ACETATE ASCORBIC ACID SODIUM METABISULFITE WATER METHYLPARABEN PROPYLPARABEN BUTYLATED HYDROXYTOLUENE Product Characteristics Color WHITE Score Shape Size Flavor Imprint Code Contains Packaging # Item Code Package Description 1 NDC:62032-117-36 57 g in 1 BOTTLE, PLASTIC Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date UNAPPROVED DRUG OTHER 01/01/1988 CONDITION AND ENHANCE BLENDER SKIN LIGHTENER AND BLENDING hydroquinone cream Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:62032-115 Route of Administration TOPICAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength HYDROQUINONE (HYDROQUINONE) HYDROQUINONE 40 mg in 1 g Inactive Ingredients Ingredient Name Strength EDETATE DISODIUM TROLAMINE SALICYLATE SODIUM LAURYL SULFATE CETYL ALCOHOL GLYCERIN LACTIC ACID ALPHA-TOCOPHEROL ACETATE ASCORBIC ACID SODIUM METABISULFITE WATER METHYLPARABEN PROPYLPARABEN BUTYLATED HYDROXYTOLUENE PHENYL TRIMETHICONE Product Characteristics Color WHITE Score Shape Size Flavor Imprint Code Contains Packaging # Item Code Package Description 1 NDC:62032-115-10 28.5 g in 1 BOTTLE, PLASTIC 2 NDC:62032-115-36 57 g in 1 BOTTLE, PLASTIC Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date UNAPPROVED DRUG OTHER 01/01/1988 Labeler - OMP, INC. (790553353) Establishment Name Address ID/FEI Operations PURETEK CORPORATION 785961046 MANUFACTURE(62032-117, 62032-115), LABEL(62032-117, 62032-115), PACK(62032-117, 62032-115) Establishment Name Address ID/FEI Operations Ei INC. 105803274 MANUFACTURE(62032-117, 62032-115), LABEL(62032-117, 62032-115), PACK(62032-117, 62032-115), ANALYSIS(62032-117, 62032-115) Revised: 12/2011 OMP, INC. Next Pregnancy Warnings Print this page Add to My Med List More about Obagi Condition and Enhance (hydroquinone topical) Side Effects During Pregnancy Dosage Information 0 Reviews Add your own review/rating Drug class: topical depigmenting agents Consumer resources Professional resources Hydroquinone (AHFS Monograph) Hydroquinone Time Release Cream (FDA) Other brands: Melamin , Lustra , Melquin HP , Melpaque HP , ... +18 more Related treatment guides Dermatological Disorders} FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx OTC Availability Rx and/or OTC C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Drug Class Topical depigmenting agents Related Drugs topical depigmenting agents hydroquinone topical , Melamin , Tri-Luma , Lustra Dermatological Disorders triamcinolone , clobetasol topical , betamethasone , Temovate , Diprolene , Analpram-HC , Celestone , urea topical , Valisone , Clobex , Proctofoam HC , sodium hyaluronate topical , hydroquinone topical , Olux , Betamethacot , Diprosone , salicylic acid topical , Melamin , Diprolene AF , Celestone Soluspan , Analpram E , Clobevate , More... Obagi Condition and Enhance Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first!} } weakness
that you can imagine Obagi Condition and Enhance most excellent
EmoticonEmoticon